Trial Profile

A Phase 2 Study of Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Copanlisib (Primary) ; Rituximab (Primary)
Indications Follicular lymphoma
Focus Therapeutic Use

Most Recent Events

12 Dec 2023 preliminary Results assessing Copanlisib and Rituximab for Untreated Follicular Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
07 Dec 2023 According to a BostonGene media release, research conducted in collaboration with the National Cancer Institute, National Institutes of Health and Mayo Clinic.
07 Dec 2023 According to a BostonGene media release, preliminary analysis from this trial will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com